Max Healthcare Institute Ltd

- Dwarka hospital (300 beds): Near commissioning; asset-light model with lease contract; minimal future CAPEX expected; finishing in progress. - Nanavati (329 beds): Basement and ground level completed; steel fabrication started; on schedule. - Sector-56 Gurgaon (300 beds): Structural drawing approved; RCC works commenced; on schedule. - Mohali (190 beds): Design finalized; base raft concrete started; on schedule. - Max Smart (Saket Complex, 350 beds): Tree transplantation underway; existing structures demolished; project progressing after initial delay. - Max Vikrant (Saket Complex, 300 beds): Revised building plans submitted; infrastructure dues paid; contractor tenders under review; Forest department NOC applied. - Expected CAPEX for FY24 is Rs. 900 crore (tracking Rs. 300 crore so far). - Lucknow expansion has land for significant future capacity (up to 3500 beds possible post-2028); construction and expansion will be phased. - Brownfield expansions like Shalimar Bagh are preferred for quicker bed additions with better operating leverage. Overall, multiple large-scale projects are underway with planned commissioning over next 1-3 years and further strategic expansions contemplated.

- Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY. - Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix. - International patient revenue grew 25% YoY, supporting revenue growth. - Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints. - Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins. - Oncology, including robotics and immunotherapy, is a key growth driver, with higher EBITDA per bed. - Institutional business tariffs may be revised upwards, potentially increasing revenue. - Seasonal patterns: Q2 & Q4 typically strongest quarters. - Overall, a robust Q4 is expected due to seasonality and continued growth momentum.

- Max Healthcare expects a robust Q4, benefiting from seasonality effects (Q2 and Q4 are typically strongest). - Existing hospitals are expected to see continued revenue growth and operating leverage, with around 7% cost growth. - New hospital beds (about 8% capacity increase) will start with lower ARPOB and negative EBITDA, breakeven expected within 6-12 months, which could temporarily temper margin expansion. - EBITDA per bed is improving, with a 15% increase noted recently, driven by case mix, ARPOB increases, and operating leverage. - Institutional business shows strong ARPOB growth (about 9-10%), and oncology and international patient growth remain key drivers. - Margin improvement may be stable to moderate in FY25, balanced between mature hospital growth and new hospital ramp-ups. - Overall, earnings growth will continue but moderated by new capacity commissioning costs.

- No explicit mention of current or expected order book or pending orders was found in the provided transcript excerpts. - The discussion primarily focuses on expansion projects, hospital bed capacity, acquisitions (e.g., Lucknow hospital), and operational performance. - Capex updates note Rs. 300 crore spent in nine months FY24 against a Rs. 900 crore guidance, with multiple hospitals (Dwarka, Nanavati, Gurgaon, Mohali) expected to commission in FY25. - No detailed order book figures or pending order specifics related to contracts or procurement are disclosed in the text. - Expansion involves organic growth and opportunistic acquisitions, with active but not aggressive pursuit of opportunities in new cities.

- There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages. - The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends. - Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing. - Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet. - For Lucknow, large-scale future capacity expansions post FY28 are described as potential, with no approved CAPEX or Board approvals currently. - Overall, the company appears financially comfortable funding growth organically without aggressive external fundraising plans at this time.